Latest Breaking News On - Biocryst pharmaceutical - Page 6 : comparemela.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Post Earnings of -$0.38 Per Share

Brokerages expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) will report earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.26). BioCryst Pharmaceuticals posted earnings per share of ($0.36) […]

Georgeb-abercrombie
Jonp-stonehouse
Dekabank-deutsche-girozentrale
Piper-sandler
Kalos-management-inc
Biocryst-pharmaceuticals-company-profile-get-rating
Zacks-investment-research
W-cole-advisors-inc
Biondo-investment-advisors
Nasdaq
Biocryst-pharmaceuticals
Jw-cole-advisors-inc

3 Healthcare Stocks With High Dividends

Looking for a healthcare stock that will pay you to own it? Here are three suggestions.

Japan
Japanese
Taylor-carmichael-amgen
George-budwell-takeda
Patrick-bafuma-petmed
Amgen
Petmed-express
Nasdaq
Motley-fool
Takeda-pharmaceutical
Biocryst-pharmaceutical

Why BioCryst Pharmaceuticals Rose 8% on Thursday

Why BioCryst Pharmaceuticals Rose 8% on Thursday
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

Biocryst-pharmaceuticals
Biocryst-pharmaceutical

Ebola Drug and Vaccine Market: North America accounted for the dominant share in the global market

Ebola Drug and Vaccine Market: North America accounted for the dominant share in the global market
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United-states
Canada
America
Rohit-bhisey
Transparency-market-research
Biocryst-pharmaceutical-inc
Tekmira-pharmaceuticals
Newlink-genetics-corp
Global-ebola-drug
Vaccines-market
West-africa
Ebola-drug

Ultrarare disease specialists top 2021's pricey drugs list, but Takeda, Merck KGaA meds rank, too

Mar 9, 2021 12:12pm Eiger BioPharmaceuticals Zokinvy, recently approved by the FDA for ultrarare rapid-aging diseases that affect an estimated 600 children worldwide, is the most expensive drug in U.S. pharmacies in 2021, according to GoodRx.(Jacoblund) Eiger BioPharmaceuticals in November snagged FDA clearance for Zokinvy for ultra-rare rapid-aging diseases that affect an estimated 600 people worldwide. Orphan drugs that treat small patient populations typically come with high prices, but Zokinvy’s sticker price now beats them all in U.S. pharmacies. At an estimated monthly price of $86,000, or more than $1 million a year, Zokinvy’s now the most expensive pharmacy drug in the U.S. as of February, according to a list compiled by GoodRx. The ranking focuses on monthly prices and doesn’t include drugs administered by doctors.

Eiger-onecare
Zokinvy-orladeyo
Amryt-pharma
Pharma-europe
Merck-kga
Merck-kgaa
Merck-co
Bristol-myers-squibb
Eiger-biopharmaceuticals
Pharma-marketing
Digital-pharma